Dataset Information

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).

ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic has infected 673,010,496 patients and caused the death of 6,854,959 cases globally until today. Enormous efforts have been made to develop fundamentally different COVID-19 vaccine platforms. Nucleic acid-based vaccines consisting of mRNA and DNA vaccines (third-generation vaccines) have been promising in terms of rapid and convenient production and efficient provocation of immune responses against the COVID-19. Several DNA-based (ZyCoV-D, INO-4800, AG0302-COVID19, and GX-19N) and mRNA-based (BNT162b2, mRNA-1273, and ARCoV) approved vaccine platforms have been utilized for the COVID-19 prevention. mRNA vaccines are at the forefront of all platforms for COVID-19 prevention. However, these vaccines have lower stability, while DNA vaccines are needed with higher doses to stimulate the immune responses. Intracellular delivery of nucleic acid-based vaccines and their adverse events needs further research. Considering re-emergence of the COVID-19 variants of concern, vaccine reassessment and the development of polyvalent vaccines, or pan-coronavirus strategies, is essential for effective infection prevention.

SUBMITTER: Baghban R

PROVIDER: S-EPMC10062302 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).

Baghban Roghayyeh R Ghasemian Abdolmajid A Mahmoodi Shirin S

Archives of microbiology 20230330 4

The coronavirus disease 2019 (COVID-19) pandemic has infected 673,010,496 patients and caused the death of 6,854,959 cases globally until today. Enormous efforts have been made to develop fundamentally different COVID-19 vaccine platforms. Nucleic acid-based vaccines consisting of mRNA and DNA vaccines (third-generation vaccines) have been promising in terms of rapid and convenient production and efficient provocation of immune responses against the COVID-19. Several DNA-based (ZyCoV-D, INO-4800 ...[more]

PMID: 36995507

Similar Datasets

Project description:IntroductionCoronavirus disease 2019 (COVID-19) vaccine hesitancy is a complex health challenge characterized by a delay in the acceptance or refusal of the vaccination with context-specific determinants. Our study, therefore, assessed the COVID-19 vaccine acceptance among urban dwellers in the Central Region, of Ghana.MethodsA cross sectional study was conducted between September and November, 2022 using a multi-stage cluster sampling procedure among 377 participants. A modified World Health Organization pretested paper-based questionnaire was administered to study participants. The data was analyzed using Statistical Package for Social Sciences (SPSS) version 26. Descriptive and inferential statistics were carried out and results were summarized into frequencies, percentages, tables, and charts for clarity. A conventional p-value < 0.05 was considered statistically significant.ResultsThe study revealed that COVID-19 vaccine acceptance was 20.0% (76/377) and vaccine hesitancy was 80.0% (301/377). Out of the 377 participants, their socio-demographic characteristics showed that the majority were below 25 years 53.8% (203/377), [vaccine acceptance; 36.84% (28/76) vs vaccine hesitancy; 58.14% (175/301)], and females 50.1% (189/377), [vaccine acceptance; 56.58% (43/76) vs vaccine hesitancy; 48.50% (146/301)]. Common reasons for COVID-19 vaccine hesitancy included mistrust of the source of the vaccine, personal belief and experience, mistrust of the drug development process, mistrust in the health system, and mistrust of the pharmaceutical company. Age above 25 years, female, educational levels, senior high school and above, being employed, and hearing of new vaccine had a significance influence on COVID-19 vaccine acceptance.ConclusionCOVID-19 vaccine acceptance was low with high vaccine hesitancy among participants. The study's findings highlights the importance of addressing vaccine hesitancy through building trust in the vaccine development processes, including the provision of accurate information about the vaccine safety and efficacy. Resolving concerns related to the source of the vaccine and the overall healthcare system are important to address vaccine hesitancy. Policy makers could adopt tailored interventions targeting specific demographic groups, such as the younger population and females to increase vaccine acceptance. Ghana's public health authorities could adopt the findings to re-strategize its urban COVID-19 vaccine campaigns to address misconceptions and misinformation to increase vaccine acceptance.

Dataset Information

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).

Publications

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets